2A Pharma is a clinical stage Swedish/Danish biopharmaceuticals company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented vaccine platform. Our lead vaccine candidate, 2AP01, is a HPV (human papillomavirus) vaccine formulated without adjuvant. We believe 2AP01 will offer significant advantages over existing vaccines including broader protection against more HPV types and lower production cost. Our vaccine technology is based on adeno-associated virus-like particles (AAVLPs), that assemble viral capsids without containing viral genomes; hence they are replicative-defective and non-pathogenic. The viral capsid has repetitive immunogenic sites that can be modified to encompass antigenic epitopes for a protein of interest, generating an immune response where both the innate and the adaptive immune system are activated. In other words, 2A Pharma exploit the efficacy of the individuals’ own immune system to generate AAVLP-based vaccines that, without the addition of adjuvants, are able to develop highly effective antibodies with selected specificities and functions. The technology enables the production of highly efficient vaccines with significant competitive advantages.
